MWA
RNTX

Meridian Wealth Advisors’s Rein Therapeutics RNTX Stock Holding History

Meridian Wealth Advisors’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.6K Hold
28,486
– – ﹤0.01% 211
2026
Q1 		$37K Hold
28,486
– – ﹤0.01% 202
2025
Q4 		$33K Hold
28,486
– – ﹤0.01% 184
2025
Q3 		$32.6K Hold
28,486
– – ﹤0.01% 186
2025
Q2 		$39.9K Hold
28,486
– – 0.01% 180
2025
Q1 		$50.4K Buy
+28,486
New +$59.8K 0.01% 170

Other funds holding RNTX

VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Meridian Wealth Advisors's RNTX Position: Q2 2026 in Review

Meridian Wealth Advisors held its Rein Therapeutics (RNTX) position steady in Q2 2026 at 28,486 shares worth $29.6K. The position accounts for ﹤0.01% of the portfolio, ranked #211.

Meridian Wealth Advisors first reported a position in RNTX in Q1 2025 and has held it in 6 quarters since. The position peaked at $50.4K in Q1 2025. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • Meridian Wealth Advisors held 28,486 shares of Rein Therapeutics worth $29.6K as of Q2 2026.
  • Meridian Wealth Advisors left its Rein Therapeutics share count unchanged in Q2 2026.
  • Rein Therapeutics made up ﹤0.01% of Meridian Wealth Advisors's portfolio in Q2 2026, its #211 holding.
  • Meridian Wealth Advisors first reported a position in Rein Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Meridian Wealth Advisors's Rein Therapeutics position peaked at $50.4K in Q1 2025.
  • 60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Meridian Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.